<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422422</url>
  </required_header>
  <id_info>
    <org_study_id>N01263</org_study_id>
    <secondary_id>2006-006536-22</secondary_id>
    <nct_id>NCT00422422</nct_id>
  </id_info>
  <brief_title>Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.</brief_title>
  <official_title>Open-Label, Single-Arm, Multicenter, Pharmacokinetic, Safety, and Efficacy Study of Adjunctive Administration of Brivaracetam in Subjects From ≥1 Month to &lt;16 Years Old With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initial study in children with epilepsy to evaluate the pharmacokinetics, safety,
      tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to
      develop dosing adaptations for future studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to &lt;2 Years</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to &lt;12 Years</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to &lt;16 Years</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Max Plasma Concentration for Age Range ≥1 Month to &lt;2 Years</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Max Plasma Concentration for Age Range ≥2 to &lt;12 Years</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Max Plasma Concentration for Age Range ≥12 to &lt;16 Years</measure>
    <time_frame>Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period</measure>
    <time_frame>Baseline to end of the 3-week evaluation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period</measure>
    <time_frame>Baseline to end of the 3-week evaluation period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Compliance With Brivaracetam Oral Solution During the 3-week Evaluation Period</measure>
    <time_frame>Baseline to the end of the 3-week evaluation period</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Brivaracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Oral solution
Evaluation period (3 weeks up-titration):
For subjects ≥8 years:
~0.4 mg/kg bid for Week 1
~0.8 mg/kg bid for Week 2
~1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
~0.5 mg/kg bid for Week 1
~1.0 mg/kg bid for Week 2
~2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
~0.8 mg/kg bid for Week 4
~0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
~1.0 mg/kg bid for Week 4
~0.5 mg/kg bid for Week 5</description>
    <arm_group_label>Brivaracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of epilepsy

          -  Subject having at least 1 seizure (any type) during the 3 weeks before first visit

          -  Stable dosing of 1-3 concomitant antiepileptic drugs

        Exclusion Criteria:

          -  Pregnant or nursing females

          -  Concomitant use of Levetiracetam

          -  Epilepsy secondary to a Progressive cerebral disease/tumor or other neurodegenerative
             disease

          -  History of status epilepticus

          -  Clinically significant acute or chronic illness, underlying disease or medication
             condition

          -  History of suicide attempt
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>108</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>110</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>106</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>113</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>114</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>109</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>117</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>203</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>502</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>504</name>
      <address>
        <city>Ostrava Porubo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>501</name>
      <address>
        <city>Praha 4</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>602</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>611</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>609</name>
      <address>
        <city>Ciuliacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>603</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>604</name>
      <address>
        <city>Mexico D.F.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>610</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>607</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>404</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>403</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>406</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>402</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>408</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>407</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>405</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>309</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>306</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>301</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>304</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>308</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>303</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>November 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2017</results_first_posted>
  <disposition_first_submitted>March 18, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 18, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 15, 2014</disposition_first_posted>
  <last_update_submitted>November 8, 2016</last_update_submitted>
  <last_update_submitted_qc>November 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brivaracetam</keyword>
  <keyword>Epilepsy</keyword>
  <keyword>Child</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The N01263 study began recruitment in July 2011, with subjects enrolled in the European Union, Mexico, and the United States. The study concluded in March 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Brivaracetam (ES)</title>
          <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SAE, non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE, non-serious non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics consists of the Enrolled Subjects analysis set, which is comprised of all subjects enrolled into the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Brivaracetam (ES)</title>
          <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.8" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Racial Group</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to &lt;2 Years</title>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (PPS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to &lt;2 Years</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.825" spread="0.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to &lt;12 Years</title>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (PPS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to &lt;12 Years</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.967" spread="0.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to &lt;16 Years</title>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (PPS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to &lt;16 Years</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.117" spread="0.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Max Plasma Concentration for Age Range ≥1 Month to &lt;2 Years</title>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (PPS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Max Plasma Concentration for Age Range ≥1 Month to &lt;2 Years</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.071" lower_limit="0.320" upper_limit="4.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Max Plasma Concentration for Age Range ≥2 to &lt;12 Years</title>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (PPS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Max Plasma Concentration for Age Range ≥2 to &lt;12 Years</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.673" lower_limit="0.561" upper_limit="5.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Max Plasma Concentration for Age Range ≥12 to &lt;16 Years</title>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (PPS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Max Plasma Concentration for Age Range ≥12 to &lt;16 Years</title>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.861" lower_limit="2.627" upper_limit="3.371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period</title>
        <time_frame>Baseline to end of the 3-week evaluation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (SS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period</title>
        <time_frame>Baseline to end of the 3-week evaluation period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (FAS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Compliance With Brivaracetam Oral Solution During the 3-week Evaluation Period</title>
        <time_frame>Baseline to the end of the 3-week evaluation period</time_frame>
        <population>Although 99 subjects were in the Safety Set and confirmed to have taken at least one dose of BRV, details on study drug intake were not able to be collected for 2 subjects. Therefore compliance could only be calculated for 97 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Brivaracetam (SS)</title>
            <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Compliance With Brivaracetam Oral Solution During the 3-week Evaluation Period</title>
          <population>Although 99 subjects were in the Safety Set and confirmed to have taken at least one dose of BRV, details on study drug intake were not able to be collected for 2 subjects. Therefore compliance could only be calculated for 97 subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;80 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 % to 120 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;120 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent Adverse Events (TEAEs) were collected during the course of the study up to day 49.</time_frame>
      <desc>The Safety Set is all enrolled subjects who took at least 1 dose of study drug.
Subjects had the ability to report more than one event. The Serious Adverse Events and Non-serious Adverse Events sections are reported in this manner.</desc>
      <group_list>
        <group group_id="E1">
          <title>Brivaracetam (SS)</title>
          <description>Brivaracetam (BRV) was given as 2 equally divided oral doses twice daily (bid). The dosage was adjusted as following:
For subjects ≥8 years:
0.4 mg/kg bid for Week 1
0.8 mg/kg bid for Week 2
1.6 mg/kg bid for Week 3
For subjects &lt;8 years:
0.5 mg/kg bid for Week 1
1.0 mg/kg bid for Week 2
2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
0.8 mg/kg bid for Week 4
0.4 mg/kg bid for Week 5
For subjects &lt;8 years:
1.0 mg/kg bid for Week 4
0.5 mg/kg bid for Week 5</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>UCB has &gt; 60 but &lt;= 180 days to review results communications prior to public release and may delete information that is confidential and compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that the results shall be published regardless of outcome.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>UCB Clinical Trial Call Center</organization>
      <phone>+1 887 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

